GABRR3

Summary

GABRR3 (gamma-aminobutyric acid type A receptor subunit rho3, HGNC:17969) is a protein-coding gene on chromosome 3q11.2, encoding Gamma-aminobutyric acid receptor subunit rho-3 (A8MPY1). Rho subunit of the pentameric ligand-gated chloride channels responsible for mediating the effects of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain.

The neurotransmitter gamma-aminobutyric acid (GABA) functions in the central nervous system to regulate synaptic transmission of neurons. This gene encodes one of three related subunits, which combine as homo- or hetero-pentamers to form GABA(C) receptors. In humans, some individuals contain a single-base polymorphism (dbSNP rs832032) that is predicted to inactivate the gene product.

Source: NCBI Gene 200959 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 99 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001105580

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17969
Approved symbol	GABRR3
Name	gamma-aminobutyric acid type A receptor subunit rho3
Location	3q11.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000183185
Ensembl biotype	protein_coding
OMIM	618668
Entrez	200959

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 retained_intron, 1 protein_coding

ENST00000470589, ENST00000472788

RefSeq mRNA: 1 — MANE Select: NM_001105580 NM_001105580

CCDS: CCDS54617

Canonical transcript exons

ENST00000472788 — 10 exons

Exon	Start	End
ENSE00001948344	97985102	97986982
ENSE00003293686	98008956	98009038
ENSE00003305476	98001615	98001767
ENSE00003328241	98012344	98012567
ENSE00003378783	98007764	98007904
ENSE00003398751	97992852	97993048
ENSE00003552676	98017655	98017722
ENSE00003622411	98025567	98025679
ENSE00003643214	98034863	98034989
ENSE00003963798	98035190	98035315

Expression profiles

Bgee: expression breadth tissue_specific, 9 present calls, max score 71.13.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2124 / max 264.7190, expressed in 7 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43347	0.2032	7
43348	0.0092	3

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	71.13	gold quality
pancreatic ductal cell	CL:0002079	60.26	silver quality
tibialis anterior	UBERON:0001385	58.74	silver quality
epithelial cell of pancreas	CL:0000083	54.68	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
lower lobe of lung	UBERON:0008949	53.85	silver quality
skin of hip	UBERON:0001554	53.56	silver quality
upper arm skin	UBERON:0004263	53.52	gold quality
ileal mucosa	UBERON:0000331	53.09	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	53.08	silver quality
pericardium	UBERON:0002407	52.00	gold quality
deltoid	UBERON:0001476	50.80	gold quality
myocardium	UBERON:0002349	50.25	gold quality
nasal cavity epithelium	UBERON:0005384	47.03	gold quality
quadriceps femoris	UBERON:0001377	46.80	gold quality
vastus lateralis	UBERON:0001379	45.40	gold quality
hindlimb stylopod muscle	UBERON:0004252	45.10	gold quality
monocyte	CL:0000576	43.55	silver quality
layer of synovial tissue	UBERON:0007616	43.55	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
muscle tissue	UBERON:0002385	43.04	gold quality
skeletal muscle tissue	UBERON:0001134	42.87	gold quality
leukocyte	CL:0000738	42.75	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
calcaneal tendon	UBERON:0003701	42.44	gold quality
upper leg skin	UBERON:0004262	41.92	silver quality
middle temporal gyrus	UBERON:0002771	41.89	gold quality
sural nerve	UBERON:0015488	41.54	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-3929	yes	82.51
E-ANND-3	yes	4.41

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• GABA(C) receptors are specifically involved in aspects of visual image motion processing in the rat brain (PMID:15617751)
• found no significant differences in either the frequencies of the GABRR1-M26V, GABRR1- H27R, GABRR2-T455M, and GABRR3-Y205X genotypes or in the frequencies of the allelic variants of these polymorphisms in patients with essential tremor (PMID:20820800)
• These results suggest association between GABRR3 rs832032 polymorphism and the risk for restless legs syndrome , and a modifier effect of GABRA4 rs2229940 on the age of onset of restless legs syndrome . (PMID:29720720)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gabrr3a	ENSDARG00000027153
danio_rerio	gabrr3b	ENSDARG00000030750
mus_musculus	Gabrr3	ENSMUSG00000074991
rattus_norvegicus	Gabrr3	ENSRNOG00000001679

Paralogs (45): GABRA3 (ENSG00000011677), GABRA1 (ENSG00000022355), CHRNA3 (ENSG00000080644), GABRP (ENSG00000094755), CHRNA4 (ENSG00000101204), GLRA2 (ENSG00000101958), GABRE (ENSG00000102287), CHRNE (ENSG00000108556), GABRA4 (ENSG00000109158), GLRB (ENSG00000109738), GABRR2 (ENSG00000111886), GABRG2 (ENSG00000113327), CHRNB4 (ENSG00000117971), CHRNA2 (ENSG00000120903), CHRNA10 (ENSG00000129749), CHRND (ENSG00000135902), CHRNA1 (ENSG00000138435), GLRA3 (ENSG00000145451), GABRA6 (ENSG00000145863), GABRB2 (ENSG00000145864), GLRA1 (ENSG00000145888), GABRR1 (ENSG00000146276), CHRNB3 (ENSG00000147432), CHRNA6 (ENSG00000147434), HTR3B (ENSG00000149305), GABRA2 (ENSG00000151834), CHRNB2 (ENSG00000160716), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRB3 (ENSG00000166206), CHRFAM7A (ENSG00000166664), HTR3A (ENSG00000166736), CHRNA5 (ENSG00000169684), CHRNB1 (ENSG00000170175), CHRNA9 (ENSG00000174343), CHRNA7 (ENSG00000175344), HTR3C (ENSG00000178084), GABRG3 (ENSG00000182256), HTR3E (ENSG00000186038), HTR3D (ENSG00000186090)

Protein

Protein identifiers

Gamma-aminobutyric acid receptor subunit rho-3 — A8MPY1 (reviewed: A8MPY1)

Alternative names: GABA(A) receptor subunit rho-3, GABA(C) receptor

All UniProt accessions (1): A8MPY1

UniProt curated annotations — full annotation on UniProt →

Function. Rho subunit of the pentameric ligand-gated chloride channels responsible for mediating the effects of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain. Rho-containing GABA-gated chloride channels are a subclass of GABA(A) receptors (GABAARs) entirely composed of rho subunits, where GABA molecules bind at the rho intersubunit interfaces. When activated by GABA, rho-GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient.

Subunit / interactions. Three rho subunits (rho-1/GBRR1, rho-2/GBRR2 and rho-3/GBRR3) coassemble either to form functional homopentamers or heteropentamers. Forms a ternary complex with SQSTM1 and PRKCZ.

Subcellular location. Postsynaptic cell membrane. Cell membrane.

Activity regulation. Inhibited by TPMPA, a rho-specific antagonist, when forming a homopentamer.

Domain organisation. GABAARs subunits share a common topological structure: a peptide sequence made up of a long extracellular N-terminal, four transmembrane domains, intracellular or cytoplasmic domain located between the third and the fourth transmembrane domains.

Polymorphism. The sequence shown in this entry differs from the translation of the reference genome assembly (GRCh38/hg38) due to a nonsense variant creating stop codon at position 205 in the reference genome. The sequence shown in this entry is that of variant p.Ter205Tyr, which has a frequency of about 79% in the human population according to the Genome Aggregation Database (gnomAD v3.1.2).

Similarity. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Gamma-aminobutyric acid receptor (TC 1.A.9.5) subfamily. GABRR3 sub-subfamily.

RefSeq proteins (1): NP_001099050* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006028	GABAA/Glycine_rcpt	Family
IPR006029	Neurotrans-gated_channel_TM	Domain
IPR006201	Neur_channel	Family
IPR006202	Neur_chan_lig-bd	Domain
IPR018000	Neurotransmitter_ion_chnl_CS	Conserved_site
IPR036719	Neuro-gated_channel_TM_sf	Homologous_superfamily
IPR036734	Neur_chan_lig-bd_sf	Homologous_superfamily
IPR038050	Neuro_actylchol_rec	Homologous_superfamily

Pfam: PF02931, PF02932

Catalyzed reactions (Rhea), 1 shown:

• chloride(in) = chloride(out) (RHEA:29823)

UniProt features (17 total): topological domain 4, transmembrane region 4, binding site 3, signal peptide 1, chain 1, region of interest 1, glycosylation site 1, disulfide bond 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A8MPY1-F1	76.27	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 111 (in chain a); 175 (in chain a); 203 (in chain b)

Disulfide bonds (1): 184–198

Glycosylation sites (1): 220

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-977443	GABA receptor activation

MSigDB gene sets: 58 (showing top): GOBP_INORGANIC_ANION_TRANSPORT, GOBP_GAMMA_AMINOBUTYRIC_ACID_SIGNALING_PATHWAY, GOBP_CELL_CELL_SIGNALING, GOBP_CHLORIDE_TRANSPORT, GOBP_SYNAPTIC_SIGNALING, REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_GABA_RECEPTOR_COMPLEX, GOCC_POSTSYNAPSE, GOCC_SYNAPSE, GOCC_CHLORIDE_CHANNEL_COMPLEX, GOCC_POSTSYNAPTIC_MEMBRANE, GOCC_TRANSPORTER_COMPLEX, GOCC_MEMBRANE_PROTEIN_COMPLEX, GOCC_RECEPTOR_COMPLEX

GO Biological Process (7): gamma-aminobutyric acid signaling pathway (GO:0007214), chemical synaptic transmission (GO:0007268), synaptic transmission, GABAergic (GO:0051932), chloride transmembrane transport (GO:1902476), monoatomic ion transport (GO:0006811), chloride transport (GO:0006821), monoatomic ion transmembrane transport (GO:0034220)

GO Molecular Function (6): GABA-A receptor activity (GO:0004890), GABA-gated chloride ion channel activity (GO:0022851), transmembrane signaling receptor activity (GO:0004888), monoatomic ion channel activity (GO:0005216), extracellular ligand-gated monoatomic ion channel activity (GO:0005230), chloride channel activity (GO:0005254)

GO Cellular Component (8): plasma membrane (GO:0005886), chloride channel complex (GO:0034707), postsynaptic membrane (GO:0045211), GABA-ergic synapse (GO:0098982), GABA-A receptor complex (GO:1902711), cellular_component (GO:0005575), membrane (GO:0016020), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Neurotransmitter receptors and postsynaptic signal transmission	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
GABA receptor activity	2
cell-cell signaling	1
anterograde trans-synaptic signaling	1
chemical synaptic transmission	1
chloride transport	1
monoatomic anion transmembrane transport	1
transport	1
monoatomic anion transport	1
inorganic anion transport	1
monoatomic ion transport	1
transmembrane transport	1
chloride channel activity	1
transmitter-gated monoatomic ion channel activity	1
ligand-gated monoatomic anion channel activity	1
signaling receptor activity	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
ligand-gated monoatomic ion channel activity	1
monoatomic anion channel activity	1
chloride transmembrane transporter activity	1
membrane	1
cell periphery	1
monoatomic ion channel complex	1
synaptic membrane	1
postsynapse	1
synapse	1
GABA receptor complex	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

368 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GABRR3	BRS3	P32247	449
GABRR3	MTNR1B	P49286	410
GABRR3	ZBTB34	Q8NCN2	386
GABRR3	RHBDD2	Q6NTF9	373
GABRR3	ABCB4	P21439	353
GABRR3	JMJD4	Q9H9V9	353
GABRR3	GAPVD1	Q14C86	343
GABRR3	IMPG1	Q17R60	339
GABRR3	DRC3	Q9H069	330
GABRR3	ADH1B	P00325	325
GABRR3	GPR156	Q8NFN8	313
GABRR3	MTNR1A	P48039	304
GABRR3	H0Y8X5	H0Y8X5	304
GABRR3	NT5DC3	Q86UY8	286
GABRR3	HS1BP3	Q53T59	284
GABRR3	ADCY2	Q08462	284

IntAct

0 interactions, top by confidence:

BioGRID (1): RAB5C (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A8MPY1, F1R8P4, O75311, O93430, P02713, P02714, P02715, P02716, P02717, P02718, P04759, P05376, P09628, P09660, P09690, P20782, P22770, P22771, P23415, P23416, P24046, P24524, P25110, P26714, P28476, P43144, P47742, P49580, P49582, P50572, P50573, P54244, P56475, P56476, P57695, Q05941, Q07001, Q08832, Q0II76, Q24352

Diamond homologs: A0A1S4H2E2, A8MPY1, D1LYT2, G5EBR3, O14764, O75311, O93430, P0C2W5, P15431, P18505, P18506, P19019, P20781, P22771, P22933, P23416, P24045, P25123, P28472, P47870, P48167, P48168, P63079, P63080, P63137, P63138, Q08832, Q61603, Q75NA5, Q7TNC8, Q94900, Q9BLY8, Q9GJS9, Q9V9Y4, F1R8P4, O00591, O09028, O18276, P07727, P08219

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	83
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1798 predictions. Top by Δscore:

Variant	Effect	Δscore
3:98017722:CCT:C	acceptor_gain	1.0000
3:98017724:T:C	acceptor_gain	1.0000
3:98025562:CTCA:C	donor_loss	1.0000
3:98025563:TCA:T	donor_loss	1.0000
3:98025564:CA:C	donor_loss	1.0000
3:98025565:A:AC	donor_gain	1.0000
3:98025565:ACCT:A	donor_gain	1.0000
3:98025566:C:CC	donor_gain	1.0000
3:98025566:CCTC:C	donor_gain	1.0000
3:98025680:C:CC	acceptor_gain	1.0000
3:98025689:C:CT	acceptor_gain	1.0000
3:98025689:C:T	acceptor_gain	1.0000
3:98025690:A:T	acceptor_gain	1.0000
3:97992855:T:A	donor_gain	0.9900
3:98012425:T:TC	acceptor_gain	0.9900
3:98017647:AAACT:A	donor_loss	0.9900
3:98017648:AACTT:A	donor_loss	0.9900
3:98017649:ACTT:A	donor_loss	0.9900
3:98017650:CTTAC:C	donor_loss	0.9900
3:98017651:TTA:T	donor_loss	0.9900
3:98017652:T:TG	donor_loss	0.9900
3:98017653:A:AT	donor_loss	0.9900
3:98017721:CC:C	acceptor_gain	0.9900
3:98017721:CCC:C	acceptor_loss	0.9900
3:98017723:C:A	acceptor_loss	0.9900
3:98017723:C:T	acceptor_gain	0.9900
3:98017724:T:G	acceptor_loss	0.9900
3:98025559:ATACT:A	donor_loss	0.9900
3:98025566:CCT:C	donor_gain	0.9900
3:98025676:TTTG:T	acceptor_gain	0.9900

AlphaMissense

3139 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:98008957:G:C	S204R	0.995
3:98008957:G:T	S204R	0.995
3:98008959:T:G	S204R	0.995
3:98007870:C:A	W216C	0.993
3:98007870:C:G	W216C	0.993
3:97992945:G:C	S337R	0.992
3:97992945:G:T	S337R	0.992
3:97992947:T:G	S337R	0.992
3:98007872:A:G	W216R	0.991
3:98007872:A:T	W216R	0.991
3:98009019:A:G	C184R	0.990
3:98012456:A:G	W140R	0.990
3:98012456:A:T	W140R	0.990
3:98012534:A:G	W114R	0.989
3:98012534:A:T	W114R	0.989
3:98012532:C:A	W114C	0.988
3:98012532:C:G	W114C	0.988
3:98001727:C:A	R265S	0.987
3:98001727:C:G	R265S	0.987
3:98001728:C:G	R265T	0.987
3:98012380:C:G	R165P	0.987
3:98001728:C:A	R265M	0.986
3:98007883:A:G	L212P	0.986
3:98008976:C:G	C198S	0.986
3:98008977:A:T	C198S	0.986
3:98008970:A:G	L200P	0.985
3:98008975:A:C	C198W	0.985
3:98008977:A:G	C198R	0.985
3:98009017:G:C	C184W	0.985
3:98009018:C:G	C184S	0.984

dbSNP variants (sampled 300 via entrez): RS1000036397 (3:98028677 G>C,T), RS1000133520 (3:97988352 A>G), RS1000174004 (3:98026158 T>C), RS1000340976 (3:98013420 C>A), RS1000394992 (3:98016510 A>T), RS1000447212 (3:98016740 T>G), RS1000458229 (3:98031790 G>A,T), RS1000473364 (3:98013631 G>T), RS1000486005 (3:97988212 A>G), RS1000498901 (3:98027682 T>G), RS1000579482 (3:98023447 C>G), RS1000583802 (3:98004983 T>C), RS1000652763 (3:98020872 T>A,C), RS1000785406 (3:98018120 A>G), RS1000802573 (3:98028978 C>T)

Disease associations

OMIM: gene MIM:618668 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): restless legs syndrome (MONDO:0005391)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D012148	Restless Legs Syndrome	C10.803; C10.886.425.800.700; C10.886.659.634; F03.870.400.800.700; F03.870.664.634

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2109242 (PROTEIN COMPLEX GROUP)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 160,188 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL96	GAMMA-AMINOBUTYRIC ACID	1	160,188

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: lgic — GABA_A receptors

Binding affinities (BindingDB)

1 measured of 2 human assays (5 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
1H-imidazol-4-ylacetic acid	KI	150 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.22	Kd	600	nM	t-4-AMINOCROTONIC ACID (TACA)
5.77	Kd	1700	nM	GAMMA-AMINOBUTYRIC ACID

PubChem BioAssay actives

2 with measured affinity, of 11 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(E)-4-aminobut-2-enoic acid	71409: Agonist activity against Gamma-aminobutyric acid type C (GABA-C) receptor derived from bovine retinal RNA expressed in Xenopus oocytes	kd	0.6000	uM
.gamma.-aminobutyric acid	71408: Agonist activity against Gamma-aminobutyric acid type C (GABA-C) receptor derived from bovine retinal RNA expressed in Xenopus oocytes	kd	1.7000	uM

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol F	affects cotreatment, decreases methylation	1
tris(2-butoxyethyl) phosphate	affects expression	1
bisphenol S	affects cotreatment, decreases methylation	1
Fulvestrant	affects cotreatment, decreases methylation	1
Benzo(a)pyrene	increases methylation	1

ChEMBL screening assays

7 unique, capped per target: 7 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL679661	Functional	Agonist activity against Gamma-aminobutyric acid C (GABA-C) receptor derived from bovine retinal RNA expressed in Xenopus oocytes	GABA-Activated ligand gated ion channels: medicinal chemistry and molecular biology. — J Med Chem

Clinical trials (associated diseases)

233 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00200941	PHASE4	COMPLETED	Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome
NCT00329602	PHASE4	COMPLETED	Long-term Study Of Ropinirole In Restless Legs Syndrome
NCT00344994	PHASE4	COMPLETED	SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
NCT00349531	PHASE4	COMPLETED	A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS
NCT00356096	PHASE4	COMPLETED	Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances
NCT00373542	PHASE4	COMPLETED	12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
NCT00375284	PHASE4	COMPLETED	A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
NCT00472199	PHASE4	COMPLETED	Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)
NCT00584246	PHASE4	WITHDRAWN	Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome
NCT01245777	PHASE4	COMPLETED	Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy
NCT01455012	PHASE4	COMPLETED	Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
NCT01668667	PHASE4	COMPLETED	Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
NCT01823770	PHASE4	COMPLETED	Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome
NCT01976871	PHASE4	COMPLETED	Switching From Oral Dopamine Agonists to Rotigotine
NCT01981941	PHASE4	COMPLETED	Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
NCT02025608	PHASE4	COMPLETED	Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome
NCT02117076	PHASE4	TERMINATED	Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome
NCT02138357	PHASE4	WITHDRAWN	Butrans for Treatment of Restless Legs Syndrome
NCT02424695	PHASE4	UNKNOWN	Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome
NCT02560766	PHASE4	UNKNOWN	An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
NCT02633683	PHASE4	UNKNOWN	An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
NCT02670161	PHASE4	ENROLLING_BY_INVITATION	Quality Improvement and Practice Based Research in Neurology Using the EMR
NCT03053427	PHASE4	COMPLETED	A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
NCT03817554	PHASE4	TERMINATED	Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients
NCT04610827	PHASE4	TERMINATED	Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
NCT04706091	PHASE4	COMPLETED	Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia
NCT05003648	PHASE4	ACTIVE_NOT_RECRUITING	Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
NCT05529095	PHASE4	UNKNOWN	Sublingual Apomorphine in Refractory Restless Legs Syndrome
NCT05581576	PHASE4	UNKNOWN	Pitolisant in Refractory Restless Legs Syndrome
NCT00133198	PHASE3	COMPLETED	Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
NCT00135993	PHASE3	COMPLETED	Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
NCT00136045	PHASE3	COMPLETED	Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome
NCT00144209	PHASE3	COMPLETED	Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome
NCT00152958	PHASE3	COMPLETED	A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)
NCT00197080	PHASE3	COMPLETED	Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
NCT00225862	PHASE3	COMPLETED	A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
NCT00256854	PHASE3	COMPLETED	Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
NCT00263068	PHASE3	COMPLETED	An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome
NCT00275236	PHASE3	COMPLETED	A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
NCT00275457	PHASE3	COMPLETED	Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients